Investigating low-pressure AI-enabled PAP therapy without compromising AHI: a win for all OSA patients

<bold>Introduction:</bold> Despite the advantage of increased comfort, low-pressure Positive Airway Pressure (PAP) therapy raises the Apnea-Hypopnea Index (AHI). We hypothesize our AI-driven cMAP™ algorithm (Hanafi. et al. ERJ 2023 62: PA573), enables PAP therapy at significantly reduced pressures while preserving efficacy. <bold>Methods:</bold> An ongoing randomized crossover study on PAP-adherent OSA patients (n=50) aims to evaluate cMAP™'s effectiveness in treating OSA with lower mean therapy pressures than conventional auto PAP (APAP). Patients undergo one week of cMAP™ (test) and one week of APAP therapy (control). Pressure and AHI are monitored via the PAP device, and the SleepImage™ Ring tracks sleep staging and SleepImage AHI (sAHI). <bold>Results:</bold> Preliminary results across subjects (2 female, 4 male, significance determined via paired t-tests) show cMAP™ delivers lower mean nightly therapy pressure than APAP (p<0.01), averaging -1.8±0.6 cmH20 (±S.D.). No differences are observed in AHI (p=0.75) or sAHI (p=0.69). 2/6 subjects spent more time in stable non-REM sleep with cMAP™ (+14% of night, p<0.05) with no differences in the remaining 4 patients. <bold>Conclusion:</bold> cMAP™ has the potential to improve pressure related comfort and quality of care. Future work includes developing a technique to tailor cMAP™’s AI component to individual subjects. <fig><object-id>erj;64/suppl_68/PA4470/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>